DK0619704T3 - Præparat til behandling af tumorer med høj tyrosinaseaktivitet - Google Patents

Præparat til behandling af tumorer med høj tyrosinaseaktivitet

Info

Publication number
DK0619704T3
DK0619704T3 DK92924270T DK92924270T DK0619704T3 DK 0619704 T3 DK0619704 T3 DK 0619704T3 DK 92924270 T DK92924270 T DK 92924270T DK 92924270 T DK92924270 T DK 92924270T DK 0619704 T3 DK0619704 T3 DK 0619704T3
Authority
DK
Denmark
Prior art keywords
treatment
tyrosinase
tyrosinase activity
tumors
preparation
Prior art date
Application number
DK92924270T
Other languages
English (en)
Inventor
David Rubin
Original Assignee
David Rubin
Schwimmer Adolph
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by David Rubin, Schwimmer Adolph filed Critical David Rubin
Application granted granted Critical
Publication of DK0619704T3 publication Critical patent/DK0619704T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
DK92924270T 1991-11-04 1992-11-04 Præparat til behandling af tumorer med høj tyrosinaseaktivitet DK0619704T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78734791A 1991-11-04 1991-11-04
PCT/US1992/009473 WO1993008688A1 (en) 1991-11-04 1992-11-04 Method and composition for treating tumors having high tyrosinase activity

Publications (1)

Publication Number Publication Date
DK0619704T3 true DK0619704T3 (da) 1999-10-11

Family

ID=25141186

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92924270T DK0619704T3 (da) 1991-11-04 1992-11-04 Præparat til behandling af tumorer med høj tyrosinaseaktivitet

Country Status (11)

Country Link
US (1) US5340803A (da)
EP (1) EP0619704B1 (da)
AT (1) ATE178211T1 (da)
AU (1) AU665220B2 (da)
CA (1) CA2122922C (da)
DE (1) DE69228829T2 (da)
DK (1) DK0619704T3 (da)
ES (1) ES2132137T3 (da)
GR (1) GR3030259T3 (da)
MX (1) MX9206309A (da)
WO (1) WO1993008688A1 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5760008A (en) * 1991-11-04 1998-06-02 Co Enzyme Technology Ltd. Method and compositions for treating malignant tumors and inhibiting metastases of malignant tumors
US5639737A (en) * 1991-11-04 1997-06-17 Co Enzyme Technology Ltd. Method and compositions for treating malignant tumors and inhibiting growth and metastases of malignant tumors
US5476842A (en) * 1991-11-04 1995-12-19 Co Enzyme Technology Ltd. Method and compositions for treating tumors having high tyrosinase activity
US5543146A (en) * 1995-01-20 1996-08-06 Prostahelp, Inc. Dietary supplement for alleviating the symptoms associated with enlargement of the prostate gland
US7635722B1 (en) * 1998-07-27 2009-12-22 Saint Jude Pharmaceuticals, Inc. Chemical induced intracellular hyperthermia
US7927612B2 (en) * 2000-01-19 2011-04-19 Baofa Yu Combinations and methods for treating neoplasms
WO2002069953A1 (en) * 2001-03-01 2002-09-12 The Board Of Regents Of The University Of Texas System Methods of treating lung inflammation
JP2004535792A (ja) * 2001-04-27 2004-12-02 ザ ジェネラル ホスピタル コーポレーション チロシナーゼアッセイ法
US7217696B2 (en) 2002-02-28 2007-05-15 A & D Bioscience, Inc. Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof
WO2003079980A2 (en) * 2002-03-19 2003-10-02 A & D Bioscience, Inc. Caboxylic acid glycuronides, glycosamides and glycosides of quinolones, penicillins, analogs, and uses thereof
US20050255038A1 (en) * 2002-04-12 2005-11-17 A And D Bioscience, Inc. Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents and uses thereof
US20050153928A1 (en) * 2002-05-07 2005-07-14 Holick Michael F. Conjugates comprising a central nervous system-active drug linked to glucuronic acid or glucosamine through an amide bond and uses thereof
US20050215487A1 (en) * 2002-06-27 2005-09-29 Holick Michael F Conjugates comprising an nsaid and a sugar and uses thereof
US7108992B2 (en) * 2002-11-27 2006-09-19 St. Jude Children's Research Hospital ATM kinase compositions and methods
US6916627B2 (en) * 2002-11-27 2005-07-12 St. Jude Children's Research Hospital ATM kinase compositions and methods
JP2009530294A (ja) * 2006-03-15 2009-08-27 マリンクロット インコーポレイテッド 置換芳香族部分を有するキレート化接合体およびその誘導体
CN101138634A (zh) * 2006-09-07 2008-03-12 于保法 用于治疗肿瘤的组合物
EP3223810A1 (en) 2014-11-26 2017-10-04 Baofa Yu Hapten-enhanced chemoimmunotherapy by ultra-minimum incision personalized intratumoral chemoimmunotherapy
WO2016196614A1 (en) * 2015-06-01 2016-12-08 University Of Kentucky Research Foundation Chloroquine induction of par-4 and treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2212014A1 (de) * 1971-04-21 1972-10-26 Deutsche Akademie der Wissenschaf ten zu Berlin, χ 1199 Berlin Verfahren zur fermentativen Spaltung von Transportformen von Chemotherapeutika, insbesondere Cancerostatica
US4481195A (en) * 1978-10-13 1984-11-06 Adolf Schwimmer Method for the treatment of tumors with β-glucuronidase activity dependent pharmaceuticals
US4424348A (en) * 1978-10-13 1984-01-03 Adolf W. Schwimmer Methods of manufacture of nitrile-containing glucuronic acid conjugates
US4337760A (en) * 1978-10-13 1982-07-06 Adolf Schwimmer Method for the treatment of tumors with β-glucuronidase activity dependent pharmaceuticals
US4812590A (en) * 1987-06-25 1989-03-14 Merck & Co., Inc. Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma

Also Published As

Publication number Publication date
EP0619704B1 (en) 1999-03-31
CA2122922A1 (en) 1993-05-13
AU3064192A (en) 1993-06-07
MX9206309A (es) 1994-05-31
DE69228829T2 (de) 1999-10-21
AU665220B2 (en) 1995-12-21
EP0619704A1 (en) 1994-10-19
DE69228829D1 (de) 1999-05-06
GR3030259T3 (en) 1999-08-31
WO1993008688A1 (en) 1993-05-13
EP0619704A4 (en) 1997-03-26
ATE178211T1 (de) 1999-04-15
CA2122922C (en) 2004-03-30
US5340803A (en) 1994-08-23
ES2132137T3 (es) 1999-08-16

Similar Documents

Publication Publication Date Title
DK0619704T3 (da) Præparat til behandling af tumorer med høj tyrosinaseaktivitet
HUS1300063I1 (hu) Egy ingenán vegyület alkalmazása rák kezelésére alkalmas gyógyszerkészítmény elõállítására
BR0207871A (pt) Composição para liberar bisfosfonato para um alvo
AU7371600A (en) Use of alpha-linolenic acid metabolites for treatment or prevention of cancer
UY26635A1 (es) Métodos sinérgicos y composiciones para el tratamiento del cáncer
WO2001039763A3 (en) Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors
NZ509028A (en) Stable extended release oral dosage composition comprising a pseudoephedrine-containing core, the core being uniformly covered with a desloratadine-containing film
GEP20043238B (en) Sulfamato Hydroxamic Acid Metalloprotease Inhibitor, its Use in Preparation of Pharmaceutical Composition for Treatment of Conditions Associated with Pathological Matrix Metalloprotease Activity
NO20014662D0 (no) Fremgangsmåter og preparater for behandling av faste tumorer
CY1105788T1 (el) Χρηση του taci σαν παραγοντα καταπολεμησης ογκων
PT1082110E (pt) Utilizacao de compostos para o aumento da actividade da desidrogenase de piruvato
EP1022026A3 (en) Pharmaceutical compositions for treating nitrate-induced tolerance
AR050045A1 (es) Derivados de pirrolo[3,4-c]pirazol activos como inhibidores de quinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden
EP1143958B8 (en) Pharmaceutical composition and use of rnsaid for treating inflammation
WO1992019617A3 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
AR034120A1 (es) Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico
AU2558300A (en) Substituted stilbene compounds with vascular damaging activity
DE60022895D1 (de) Pdgf-rezeptor-kinase hemmende verbindungen, deren herstellung, reinigung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
NO20004162D0 (no) Antitumor agens
DE59911734D1 (de) Kombination von selen-haltigen verbindungen mit gemcitabin oder mitomycin c
CA2458318A1 (en) Wortmannin analogs and methods of using same
DE60123117D1 (de) Verwendung von alpha-halogenacryloyl-distamycin derivaten zur herstellung eines medikaments zur behandlung von krebs
GEP20063754B (en) Quinoline Derivatives and Use Thereof as Antitumor Agents
JIMBOW et al. Phenolic melanin precursors provide a rational approach to the design of antitumor agents for melanoma
AR034398A1 (es) Homologos de 15-hete con 3-heteroatomos sustituidos y dos atomos de carbono del acido hidroxieicosatetraenoico, composicion que los contiene y el uso de la misma para la manufactura de un medicamento